The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity

Journal of Alzheimer's Disease

Volumn 26, Issue 2, 2011, Pages 387-408

  Hook, Gregory ^a   Hook, Vivian ^b   Kindy, Mark ^c,d,e  

^a American Life Science Pharmaceuticals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Applied Neurotechnology Inc   (United States)

Author keywords

Alzheimer disease; amyloid ; BACE1; cathepsin B; guinea pig; memory deficits; oral E64d; transgenic mice

Indexed keywords

ALOXISTATIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BETA SECRETASE 1; CATHEPSIN B;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; GUINEA PIG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

EID: 80052821752     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110101     Document Type: Article

References (92)

1. Sisodia SS (1999) Alzheimer's disease: perspectives for the new millennium. J Clin Invest 104, 1169-1170. (Pubitemid 29536286)
2. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
3. Gandy S, Martins RN, Buxbaum J (2003) Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 17, 259-266. (Pubitemid 37521282)
4. McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22, 281-289.
5. Dodart JC, Mathis C, Bales KR, Paul SM (2002) Does my mouse have Alzheimer's disease? Genes Brain Behav 1, 142-155. (Pubitemid 36717672)
6. van Leuven F (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61, 305-312. (Pubitemid 30155723)
7. Dewachter I, Van Leuven F (2002) Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 1, 409-416. (Pubitemid 37159151)
8. Turner RS (2006) Alzheimer's disease. Semin Neurol 26, 499-506. (Pubitemid 44631072)
9. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function.J Biol Chem 283, 29615-29619.
10. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. Neuro-molecular Med 12, 1-12.
11. Kawahara M (2010) Neurotoxicity of beta-amyloid protein: oligomerization, channel formation, and calcium dyshome-ostasis. Curr Pharm Des 16, 2779-2789.
12. Crews L, Masliah E (2010) Molecular mechanisms of neu-rodegeneration in Alzheimer's disease. Hum Mol Genet 19, R12-R20.
13. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35, 352-358.
14. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 95, 12683-12688. (Pubitemid 28483825)
15. Taylor CJ, Ireland DR, Ballagh I, Bourne K, Marechal NM, Turner PR, Bilkey DK, Tate WP, Abraham WC (2008) Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 31, 250-260.
16. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
17. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP (1991) Conservation of the sequence of the Alzheimer's disease amyloid peptideindog, polar bear andfive other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 10, 299-305.
18. Beck M, Muller D, Bigl V (1997) Amyloid precursor protein in guinea pigs-complete cDNA sequence and alternative splicing. Biochim Biophys Acta 1351, 17-21. (Pubitemid 27117462)
19. Beck M, Bigl V, Rossner S (2003) Guinea pigs as a non-transgenic model for APP processing in vitro and in vivo. Neurochem Res 28, 637-644. (Pubitemid 36314857)
20. Ashe KH, Zahs KR (2010) Probingthe biologyofAlzheimer's disease in mice. Neuron 66, 631-645.
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
22. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1, 345-347.
23. Hook V, Hook G, Kindy M (2010) Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biological Chemistry 391, 861-872.
24. Cairns NJ, Chadwick A, Lantos PL, Levy R, Rossor MN (1993) Beta A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease. Neurosci Lett 149, 137-140. (Pubitemid 23036899)
25. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early pheno-typic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274, 6483-6492. (Pubitemid 29111064)
26. Tanghe A, Termont A, Merchiers P, Schilling S, Demuth HU, Scrocchi L, Van Leuven F, Griffioen G, Van Dooren T (2010) Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London Transgenic mouse model. Int J Alzheimers Dis 2010.
27. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14, 419-427. (Pubitemid 30026585)
28. Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96, 11049-11053. (Pubitemid 29487325)
29. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
30. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gur-ney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
31. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97, 1456-1460. (Pubitemid 30118462)
32. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. JBiol Chem 277, 4687-4693. (Pubitemid 34968499)
33. Shi XP, Chen E, Yin KC, Na S, Garsky VM, Lai MT, Li YM, Platchek M, Register RB, Sardana MK, Tang MJ, Thiebeau J, Wood T, Shafer JA, Gardell SJ (2001) The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J Biol Chem 276, 10366-10373.
34. Schechter I, Ziv E (2008) Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate (s). Biol Chem 389, 313-320. (Pubitemid 351329023)
35. Hook V, Toneff T, Bogyo M, Medzihradszky K, F, Nevenu J, Lane W, Hook G, Reisine T (2005) Inhibition of cathepsin B reduces ß-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate ß-secretase of Alzheimer's disease Biological Chemistry 386, 931-940. (Pubitemid 41448149)
36. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G (2009) Genetic cathepsin B deficiency reduces beta-amyloid in trans-genic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun 386, 284-288.
37. Hook VY, Kindy M, Hook G (2008) Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem 283, 7745-7753.
38. Klein DM, Felsenstein KM, Brenneman DE (2009) Cathep-sins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther 328, 813-821.
39. Hook G, Hook VY, Kindy M (2007) Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem 388, 979-983. (Pubitemid 47258539)
40. Hook V, Kindy M, Hook G (2007) Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem 388, 247-252. (Pubitemid 46184154)
41. Hook VY, Kindy M, Hook G (2008) Inhibitors of cathepsin B improve memory and reduce Abeta in transgenic Alzheimer's Disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase APP site. JBiol Chem 283, 7745-7753.
42. Tamai M, Matsumoto K, Omura S, Koyama I, Ozawa Y, Hanada K (1986) In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J Pharmacobiodyn 9, 672-677. (Pubitemid 17170278)
43. Barrett A, Rawlings N, Woessner J (2004) Handbook of Pro-teolytic Enzymes Elsevier Academic Press, pp. 1079-1113.
44. Sadaghiani AM, Verhelst SH, Gocheva V, Hill K, Majerova E, Stinson S, Joyce JA, Bogyo M (2007) Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem Biol 14, 499-511. (Pubitemid 46765146)
45. Wang KK, Yuen PW (1994) Calpain inhibition:anoverviewof its therapeutic potential. Trends Pharmacol Sci 15, 412-419. (Pubitemid 24360511)
46. Tamai M, Yokoo C, Murata M, Oguma K, Sota K, Sato E, Kanaoka Y (1987) Efficient synthetic method for ethyl (+)-(2S, 3S)-3-[(S)-3-methyl-1-(3- methylbutylcarbamoyl) butylcarbamoyl]-2-oxiranecarb oxylate (EST), a new inhibitor of cysteine proteinases. Chem Pharm Bull (Tokyo) 35, 1098-1104. (Pubitemid 17057098)
47. Caroni P (1997) Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods 71, 3-9. (Pubitemid 27145767)
48. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60. (Pubitemid 14088970)
49. Liang KC, Hon W, Tyan YM, Liao WL (1994) Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. Chin J Physiol 37, 201-212.
50. Noble JE, Bailey MJ (2009) Quantitation of protein. Methods Enzymol 463, 73-95.
51. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913. (Pubitemid 36889934)
52. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, Masliah E, Hersh LB (2004) Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci 22, 5-11. (Pubitemid 41359010)
53. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phe-notype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232. (Pubitemid 32194866)
54. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levelsof amyloid beta-peptidein the brain and cognitive decline. JAMA 283, 1571-1577. (Pubitemid 30161512)
55. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
56. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
57. Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC (1993) Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 50, 349-358. (Pubitemid 23105458)
58. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glu-taminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 14, 1106-1111.
59. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid beta-peptides-AbetaN3 (pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 82, 1480-1489.
60. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393-12399. (Pubitemid 44583682)
61. He W, Barrow CJ (1999) The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 38, 10871-10877.
62. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gam-betti P, Tabaton M (2005) Beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280, 34186-34192. (Pubitemid 41443143)
63. Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O (2008) Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 118, 2796-2807.
64. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B:implications for Alzheimer's disease. Neuron 51, 703-714. (Pubitemid 44374903)
65. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90, 2628-2632. (Pubitemid 23113469)
66. Tsuchiya K, Kohda Y, Yoshida M, Zhao L, Ueno T, Yamashita J, Yoshioka T, Kominami E, Yamashima T (1999) Postictal blockadeofischemic hippocampal neuronal deathin primates using selective cathepsin inhibitors. Exp Neurol 155, 187-194. (Pubitemid 29124712)
67. Yoshida M, Yamashima T, Zhao L, Tsuchiya K, Kohda Y, Tonchev AB, Matsuda M, Kominami E (2002) Primate neurons show different vulnerability to transient ischemia and responsetocathepsin inhibition.Acta Neuropathol (Berl) 104, 267-272. (Pubitemid 36075387)
68. Inuzuka T, Tamura A, Sato S, Kirino T, Toyoshima I, Miyatake T (1990) Suppressive effectofE-64conischemic degradation of cerebral proteins following occlusionofthe middle cerebral artery in rats. Brain Res 526, 177-179. (Pubitemid 20273582)
69. Tsubokawa T, Yamaguchi-Okada M, Calvert JW, Solaroglu I, Shimamura N, Yata K, Zhang JH (2006) Neurovascular and neuronal protection by E64d after focal cerebral ischemia in rats. J Neurosci Res 84, 832-840. (Pubitemid 44366684)
70. Cataldo AM, Nixon RA (1990) Enzymatically active lyso-somal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA 87, 3861-3865.
71. Nakamura Y, Takeda M, Suzuki H, Hattori H, Tada K, Hariguchi S, Hashimoto S, Nishimura T (1991) Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease. Neurosci Lett 130, 195-198.
72. Cataldo AM, Paskevich PA, Kominami E, Nixon RA (1991) Lysosomal hydrolases of different classes are abnormally dis-tributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci USA 88, 10998-11002. (Pubitemid 21915966)
73. Bernstein HG, Kirschke H, Wiederanders B, Schmidt D, Rinne A (1990) Antigenic expression of cathepsin B in aged human brain. Brain Res Bull 24, 543-549. (Pubitemid 20161515)
74. Nakanishi H, Tominaga K, Amano T, Hirotsu I, Inoue T, Yamamoto K (1994) Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. Exp Neurol 126, 119-128. (Pubitemid 24131109)
75. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7, 125-133; discussion 173-180. (Pubitemid 40592186)
76. Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L (2010) Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis 22, 1223-1230.
77. Turk V, Turk B, Turk D (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20, 4629-4633. (Pubitemid 32848615)
78. Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120, 3421-3431.
79. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13, 387-403. (Pubitemid 46477760)
80. Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477, 98-111. (Pubitemid 30119895)
81. Kuliawat R, Klumperman J, Ludwig T, Arvan P (1997) Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic beta-cells. J Cell Biol 137, 595-608. (Pubitemid 27200663)
82. Petanceska S, Burke S, Watson SJ, Devi L (1994) Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: an in situ hybridization study. Neuroscience 59, 729-738. (Pubitemid 24131525)
83. Reinheckel T, Deussing J, Roth W, Peters C (2001) Towards specific functions of lysosomal cysteine peptidases: pheno-types of mice deficient for cathepsin B or cathepsin L. Biol Chem 382, 735-741. (Pubitemid 32631710)
84. Satoyoshi E (1992) Therapeutic trialsonprogressivemuscular dystrophy. Intern Med 31, 841-846.
85. Setoyama K, Koike M, Abe S, Tsutsui Y, Tarumoto Y, Nakane S (1986) Toxicological Studies of Ethyl (+)-(2S, 3S)-3-[(S)-3-methyl-1-(3- methylbutylcarbamoyl) butylcarbamoyl]-2-oxiranecarboxylate (EST) (Report 1): Acute Toxicity Studies of EST and Metabolite and By-Product of EST. Iyakuhin Kenkyu 17, 736-743
86. Fukushima K, Arai M, Kohno Y, Suwa T, Satoh T (1990) An epoxysuccinic acid derivative (loxistatin)-induced hepatic injuryinrats and hamsters.Toxicol Appl Pharmacol105, 1-12. (Pubitemid 20287018)
87. Ueki S, Watanabe S, Fujiwara M, Shibata S, Shiyu L, Iwazaki K, Ohta H, Shimazoe T (1986) Effect of cysteine proteinase inhibitor EST on central nervous system. Yakuri to Chiryo 14, 725-735
88. Hukuhara T, Kimura N, Takano K, Hachiya Y (1985) Effect of EST (E-64-d) on respiratory and cardiovascular functions and central nervous system. Tokyo Jikeikai Ika Daigaku Zasshi 100, 1207-1214. (Pubitemid 16229183)
89. Miyahara T, Shimojo S, Toyohara K, Imai T, Miyajima M, Honda H, Kamegai M, Ohzeki M, Kokatsu J (1985) Clinical Phase I trial of thiol protease inhibitor (Report 2): safety and pharmacokinetics in continuous administration. Rinsho Yakuri 16, 537-546.
90. Miyahara T, Shimojo S, Toyohara K, Imai T, Miyajima M, Honda H, Kamegai M, Ohzeki M, Kokatsu J (1985) Phase I clinical trial of thiol protease inhibitor EST (Report 1): Safety and pharmacokinetics with single administration. Rin-sho Yakuri 16, 357-365.
91. Watanabe T, Fukushima K, Ushiyama Y, Noda K, Suwa T (1986) Pharmacokinetics of EST (Report 5): Pharmacokinet-ics of EST ih humans. Kiso to Rinsho 20, 362-366.
92. Imahori K, Sugita H, Miyatake T, Ishihara T, Miyatani N, Kuwabara T (1985) Pharmacokinetics and safety of thiol protease inhibitor EST in patients with muscle disease. Rinsho Yakuri 16, 749-757.